{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:32:44Z","timestamp":1777858364176,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To determine the efficacy and safety of antipsychotic medication for treating individuals with a dual diagnosis of intellectual disability (ID) and schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically reviewed the literature to explore the risks and benefits of antipsychotics for schizophrenia in ID. In addition, a cross-sectional retrospective study on the tolerance profiles of a representative ID and schizophrenia cohort was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From the systematic search, we retained 18 articles detailing information on 24 cases. In almost all cases, the antipsychotic improved psychotic symptoms (e.g., hallucinations, delusions, disorganization). Negative manifestations were also improved (blunted affects, amotivation, poor rapport), as were challenging behaviors in a few cases. The most commonly reported side effects were neurological (extra-pyramidal, movement disorder, epilepsy) and metabolic manifestations. In the retrospective cross-sectional study, we reported data on 112 participants with comorbid ID and schizophrenia. In all, 103 participants were antipsychotic-treated, of which 39% were on antipsychotic monotherapy. Of these, 35% were in the obesity range, 25% in the hyperglycemic range, and 25% in the dyslipidemia range. The body mass index did not differ between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study provides an initial evidence base underpinning the efficacy of antipsychotic drugs on schizophrenia in the ID population. Nevertheless, there may be an increased risk of metabolic side effects, hence, close monitoring of blood glucose, lipids, and weight should be implemented when prescribing antipsychotics to this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811241276787","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T22:22:35Z","timestamp":1726266155000},"page":"1045-1053","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antipsychotic medication in people with intellectual disability and schizophrenia: A 25-year updated systematic review and cross-sectional study"],"prefix":"10.1177","volume":"38","author":[{"given":"Elsa","family":"Courtial","sequence":"first","affiliation":[{"name":"University Grenoble Alpes, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Pouchon","sequence":"additional","affiliation":[{"name":"University Grenoble Alpes, Grenoble, France"},{"name":"INSERM, U1216, Grenoble, France"},{"name":"Psychiatry Department, CHU Grenoble Alpes, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mircea","family":"Polosan","sequence":"additional","affiliation":[{"name":"University Grenoble Alpes, Grenoble, France"},{"name":"INSERM, U1216, Grenoble, France"},{"name":"Psychiatry Department, CHU Grenoble Alpes, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-8769","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Dond\u00e9","sequence":"additional","affiliation":[{"name":"University Grenoble Alpes, Grenoble, France"},{"name":"INSERM, U1216, Grenoble, France"},{"name":"Psychiatry Department, CHU Grenoble Alpes, Grenoble, France"},{"name":"Psychiatry Department, CH Alpes-Is\u00e8re, Saint-Egr\u00e8ve, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.1.42"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2020.18.4.627"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.022483"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2009.tb00199.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2009.tb00248.x"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1179\/096979509799103151"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.12.010"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-022-01544-z"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1999.00181.x"},{"key":"e_1_3_2_11_1","unstructured":"National Institute for Health and Care Excellence: Guidelines (2015) Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities Whose Behaviour Challenges. London: National Institute for Health and Care Excellence (NICE)."},{"key":"e_1_3_2_12_1","unstructured":"Fagot-Campagna A Romon I Fosse S et al (2010) Pr\u00e9valence et incidence du diab\u00e8te et mortalit\u00e9 li\u00e9e au diab\u00e8te en France\u2014Synth\u00e8se \u00e9pid\u00e9miologique. p. 4\/Institut de veille sanitaire. Available at: https:\/\/www.santepubliquefrance.fr\/content\/download\/185151\/2315077 (accessed 03 2024)."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.104.434.201"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.110.085670"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jar.12996"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2005.00708.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028125"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.08.012"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.117.005462"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2002.0988g.x"},{"key":"e_1_3_2_21_1","article-title":"COVID-19 pandemic-delayed diagnosis and treatment of atypical neuroleptic malignant syndrome in a violent forensics patient with intellectual disability and treatment-resistant schizophrenia","volume":"15","author":"Jan MZH","year":"2023","unstructured":"Jan MZH, Figgs P, Gallucci G, et al (2023) COVID-19 pandemic-delayed diagnosis and treatment of atypical neuroleptic malignant syndrome in a violent forensics patient with intellectual disability and treatment-resistant schizophrenia. Cureus 15: e41866.","journal-title":"Cureus"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01730-X"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01556-4"},{"key":"e_1_3_2_24_1","article-title":"Brief psychotic episode in a patient with chromosome 2q37 microdeletion syndrome","volume":"2017","author":"Lally K","year":"2017","unstructured":"Lally K, Ibrahim N, Kelly M, et al (2017) Brief psychotic episode in a patient with chromosome 2q37 microdeletion syndrome. BMJ Case Rep 2017: bcr2017221012.","journal-title":"BMJ Case Rep"},{"key":"e_1_3_2_25_1","first-page":"710","article-title":"Cholest\u00e9rol LDL chez les adultes en France m\u00e9tropolitaine: Concentration moyenne, connaissance et traitement en 2015, \u00e9volutions depuis 2006","volume":"37","author":"Lecoffre C","year":"2018","unstructured":"Lecoffre C, Perrine A-L, Blacher J, et al (2018) Cholest\u00e9rol LDL chez les adultes en France m\u00e9tropolitaine: Concentration moyenne, connaissance et traitement en 2015, \u00e9volutions depuis 2006. Bull Epid\u00e9miol Hebd 37: 710\u2013718.","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv037"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-017-1420-2"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721004128"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.1.116"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr148"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.044461"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02691-y"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13361"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0000000000000302"},{"key":"e_1_3_2_37_1","volume-title":"Psychotropic Drug Prescribing for People With Intellectual Disability, Mental Health Problems and\/or Behaviours that Challenge: Practice Guidelines","author":"Psychiatrists RCo","year":"2016","unstructured":"Psychiatrists RCo (2016) Psychotropic Drug Prescribing for People With Intellectual Disability, Mental Health Problems and\/or Behaviours that Challenge: Practice Guidelines. London, UK: Royal College of Psychiatrists."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2006.00865.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1556\/650.2023.32764"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970701599060"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35754"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106067765"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30191-2"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017406"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674221149864"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1744629513495261"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e318172b42d"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_405_16"},{"key":"e_1_3_2_49_1","article-title":"Kallmann syndrome and paranoid schizophrenia: A rare combination","volume":"2013","author":"Verhoeven WM","year":"2013","unstructured":"Verhoeven WM, Egger JI, Hovens JE, et al (2013) Kallmann syndrome and paranoid schizophrenia: A rare combination. BMJ Case Rep 2013: bcr2012007387.","journal-title":"BMJ Case Rep"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12861"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2004.02.018"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241276787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811241276787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241276787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:50Z","timestamp":1777507910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811241276787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/02698811241276787"],"URL":"https:\/\/doi.org\/10.1177\/02698811241276787","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}